Conventional Wisdom versus Actual Outcomes: Challenges in the Conduct of an Ebola Vaccine Trial in Liberia during the International Public Health Emergency
Clinical trials are challenging endeavors. Planning and implementing an investigational vaccine trial in Liberia, in the midst of an Ebola virus disease (EVD) epidemic that World Health Organization classified a public health emergency of international concern, presented extraordinary challenges. No...
Saved in:
Published in: | The American journal of tropical medicine and hygiene Vol. 97; no. 1; pp. 10 - 15 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
The American Society of Tropical Medicine and Hygiene
01-07-2017
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Clinical trials are challenging endeavors. Planning and implementing an investigational vaccine trial in Liberia, in the midst of an Ebola virus disease (EVD) epidemic that World Health Organization classified a public health emergency of international concern, presented extraordinary challenges. Normally, years of preparation and a litany of tasks lay the groundwork for a successful, randomized, blinded, placebo-controlled trial focused on safety and efficacy. Difficult research settings, unpredictable events, and other unique circumstances can add complexity. The setting in Liberia was especially problematic due to an infrastructure still badly damaged following a lengthy civil war and a very fragile health-care system that was further devastated by the EVD outbreak. The Partnership for Research on Vaccines in Liberia I EVD vaccine trial was planned and implemented in less than 3 months by a Liberian and U.S. research partnership, and its Phase II substudy was fully enrolled 3 months later. Contrasting conventional wisdom with trial outcomes offers an opportunity to compare early assumptions, barriers encountered, and adaptive strategies used, with end results. Understanding what was learned can inform future trial responses when disease outbreaks, especially in resource-poor locations with minimal infrastructure, pose a significant threat to public health. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Authors’ addresses: Gregg S. Larson, Coordinating Centers for Biometric Research, Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, E-mail: larso279@umn.edu. Beth R. Baseler and Wissedi Sio Njoh, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, E-mails: bbaseler@mail.nih.gov and wissedi.njoh@nih.gov. Marie L. Hoover, Advanced BioMedical Laboratories, LLC, Cinnaminson, NJ, E-mail: marie.hoover@abiolab.com. Jerome F. Pierson and Laura A. McNay, National Institute of Allergy and Infectious Diseases, Rockville, MD, E-mails: piersonjer@niaid.nih.gov and lmcnay@niaid.nih.gov. Jemee K. Tegli, Melvin P. Johnson, and Mark W. S. Kieh, Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia, E-mails: jemee.tegli@prevailcr.org, melvin.johnson@prevailcr.org, and mark.kieh@prevailcr.org. Financial support: PREVAIL research was funded by the National Cancer Institute, National Institutes of Health, Contract No. HHSN261200800001E, with the support of the National Institute of Allergy and Infectious Diseases. Trial registration number—PREVAIL I: NCT02344407. |
ISSN: | 0002-9637 1476-1645 |
DOI: | 10.4269/ajtmh.16-1015 |